VA
JBIO

VR Adviser’s Jade Biosciences JBIO Stock Holding History

VR Adviser’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$71.6M Hold
3,220,364
– – 2.17% 9
2026
Q1 		$45.2M Hold
3,220,364
– – 1.69% 17
2025
Q4 		$49.7M Hold
3,220,364
– – 2.45% 12
2025
Q3 		$27.8M Hold
3,220,364
– – 1.56% 19
2025
Q2 		$32.2M Buy
+3,220,364
New +$110M 2.41% 12
2023
Q2 		– Sell
-23,826
Closed -$16.8M – 32
2023
Q1 		$16.8M Buy
23,826
+2,458
+12% +$2.04M 3.28% 12
2022
Q4 		$21.9M Sell
21,368
-2,458
-10% -$1.78M 3.69% 9
2022
Q3 		$13.8M Buy
23,826
+6,957
+41% +$4.64M 2.13% 16
2022
Q2 		$9.23M Buy
16,869
+12,554
+291% +$6M 1.82% 16
2022
Q1 		$2.77M Buy
+4,315
New +$1.67M 0.45% 26

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

VR Adviser's JBIO Position: Q2 2026 in Review

VR Adviser held its Jade Biosciences (JBIO) position steady in Q2 2026 at 3,220,364 shares worth $71.6M. The position accounts for 2.17% of the portfolio, ranked #9.

VR Adviser first reported a position in JBIO in Q1 2022 and has held it in 10 quarters since. 154 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • VR Adviser held 3,220,364 shares of Jade Biosciences worth $71.6M as of Q2 2026.
  • VR Adviser left its Jade Biosciences share count unchanged in Q2 2026.
  • Jade Biosciences made up 2.17% of VR Adviser's portfolio in Q2 2026, its #9 holding.
  • VR Adviser first reported a position in Jade Biosciences in Q1 2022 and has held it in 10 quarters since.
  • 154 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on VR Adviser's 13F filing for Q2 2026, filed 14 Aug 2026.